Table 1.
Demographics and clinical characteristics of study patients.
| Total patients (n = 106) | Group A (n = 29) | Group B (n = 77) | P | |
|---|---|---|---|---|
| Eyes, n (%) | 108 (100) | 31 (28.70) | 77 (71.30) | |
| Mean age, years | 48.45 (9.13) | 52.28 (6.87) | 46.78 (9.45) | <0.001∗ |
| Male, n (%) | 79 (74.53) | 20 (68.97) | 59 (76.62) | 0.578† |
| HTN, n (%) | 16 (15.09) | 7 (24.14) | 9 (11.69) | 0.196† |
| DM, n (%) | 6 (5.66) | 0 (0.00) | 6 (7.79) | 0.282† |
| BCVA, logMAR | ||||
| Initial | 0.275 (0.279) | 0.342 (0.365) | 0.248 (0.233) | 0.192‡ |
| Final | 0.167 (0.176) | 0.206 (0.188) | 0.151 (0.170) | 0.158‡ |
| Follow-up duration, months | 35.56 (37.75) | 51.48 (47.42) | 29.14 (31.21) | 0.006‡ |
| Recurrence, n (%) | 0.032† | |||
| Recurrence | 48 (44.44) | 19 (61.29) | 29 (37.66) | |
| No recurrence | 60 (55.56) | 12 (38.71) | 48 (62.34) | |
| Chronicity, n (%) | 0.156† | |||
| Yes | 80 (74.07) | 26 (83.87) | 54 (70.13) | |
| No | 28 (25.93) | 5 (16.13) | 23 (29.87) | |
| Treatment, n (%) | ||||
| Anti-VEGF | 73 (67.59) | 22 (70.97) | 51 (66.23) | 0.592† |
| PDT or focal laser | 55 (50.93) | 16 (51.61) | 37 (48.05) | 0.903† |
Data are presented as mean (standard deviation) unless otherwise indicated. ∗Student's t-test; †chi-squared test; ‡Wilcoxon rank-sum test. HTN, hypertension; DM, diabetes mellitus; BCVA, best-corrected visual acuity; logMAR, logarithm of minimal angle of resolution; anti-VEGF, antivascular endothelial growth factor; PDT, photodynamic therapy.